AlloSource03.03.16
Like many of the companies attending the American Academy of Orthopaedic Surgeons 2016 Annual Meeting in Orlando, Fla., this week, AlloSource used the event to its advantage, launching its ProChondrix Cartilage Restoration Matrix, a cellular 3D fresh cartilage allograft that helps provide the necessary components for cartilage regeneration.
This patented, next-generation of cartilage therapy is designed to match the biomechanical and biochemical properties of normal hyaline cartilage, restore a smooth articular cartilage surface, and relieve patient symptoms and improve function.
"One of the most important ways we honor tissue donors is through our commitment to innovation," AlloSource President/CEO Thomas Cycyota said. "ProChondrix provides the opportunity to both maximize the donor's gift, while also helping recipients get their mobility back."
ProChondrix offers an extracellular matrix to help support a structure for cellular migration and adhesion, while preserving growth factors. The presence of native growth factors helps maintain healthy cartilage and facilitate chondrocyte functionality. ProChondrix also contains viable chondrocytes that can aid in cartilage repair by generating extracellular matrix proteins to help promote chondrogenesis.
"We discovered without the regeneration of new cartilage, many patients who had a successful microfracture surgery required a partial or full knee replacement in as few as five years' time," said Vishal Mehta, M.D., an orthopedic surgeon. "ProChondrix works by enhancing the success of a microfracture surgery and allowing the affected area to more naturally heal and rebuild strength."
Based in Centennial, Colo., AlloSource is one of the largest U.S. non-profit cellular and tissue networks, offering more than 200 types of precise cartilage, cellular, bone, skin and soft tissue allografts to advance patient healing. The company is accredited by the American Association of Tissue Banks. Its products offer life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma, and wound care procedures.
This patented, next-generation of cartilage therapy is designed to match the biomechanical and biochemical properties of normal hyaline cartilage, restore a smooth articular cartilage surface, and relieve patient symptoms and improve function.
"One of the most important ways we honor tissue donors is through our commitment to innovation," AlloSource President/CEO Thomas Cycyota said. "ProChondrix provides the opportunity to both maximize the donor's gift, while also helping recipients get their mobility back."
ProChondrix offers an extracellular matrix to help support a structure for cellular migration and adhesion, while preserving growth factors. The presence of native growth factors helps maintain healthy cartilage and facilitate chondrocyte functionality. ProChondrix also contains viable chondrocytes that can aid in cartilage repair by generating extracellular matrix proteins to help promote chondrogenesis.
"We discovered without the regeneration of new cartilage, many patients who had a successful microfracture surgery required a partial or full knee replacement in as few as five years' time," said Vishal Mehta, M.D., an orthopedic surgeon. "ProChondrix works by enhancing the success of a microfracture surgery and allowing the affected area to more naturally heal and rebuild strength."
Based in Centennial, Colo., AlloSource is one of the largest U.S. non-profit cellular and tissue networks, offering more than 200 types of precise cartilage, cellular, bone, skin and soft tissue allografts to advance patient healing. The company is accredited by the American Association of Tissue Banks. Its products offer life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma, and wound care procedures.